TY - JOUR
T1 - Anti-NMDA-Receptor Encephalitis
T2 - From Bench to Clinic
AU - Venkatesan, Arun
AU - Adatia, Krishma
N1 - Funding Information:
*Mailing address: Johns Hopkins Hospital, 600 N. Wolfe St., Meyer 6-113, Baltimore, MD 21287, USA. E-mail: avenkat2@ jhmi.edu. ORCID Arun Venkatesan: 0000-0002-9335-7361 Funding This work was supported by the National Institutes of Health (NINDS R21 NS098229 to A.V.). Notes The authors declare no competing financial interest.
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/12/20
Y1 - 2017/12/20
N2 - NMDAR encephalitis is a common cause of autoimmune encephalitis, predominantly affecting young adults. Current data supports the idea that autoantibodies targeting NMDARs are responsible for disease pathogenesis. While these autoantibodies occur in the setting of underlying malignancy in approximately half of all patients, initiating factors for the autoimmune response in the remainder of patients are unclear. While there is increasing evidence supporting viral triggers such as herpes simplex encephalitis, this association and the mechanism of action have not yet been fully described. Although the majority of patients achieve good outcomes, those without an underlying tumor consistently show worse outcomes, prolonged recovery, and more frequent relapses. The cloning of patient-specific autoantibodies from affected individuals has raised important questions as to disease pathophysiology and clinical heterogeneity. Further advances in our understanding of this disease and underlying triggers are necessary to develop treatments which improve outcomes in patients presenting in the absence of tumors.
AB - NMDAR encephalitis is a common cause of autoimmune encephalitis, predominantly affecting young adults. Current data supports the idea that autoantibodies targeting NMDARs are responsible for disease pathogenesis. While these autoantibodies occur in the setting of underlying malignancy in approximately half of all patients, initiating factors for the autoimmune response in the remainder of patients are unclear. While there is increasing evidence supporting viral triggers such as herpes simplex encephalitis, this association and the mechanism of action have not yet been fully described. Although the majority of patients achieve good outcomes, those without an underlying tumor consistently show worse outcomes, prolonged recovery, and more frequent relapses. The cloning of patient-specific autoantibodies from affected individuals has raised important questions as to disease pathophysiology and clinical heterogeneity. Further advances in our understanding of this disease and underlying triggers are necessary to develop treatments which improve outcomes in patients presenting in the absence of tumors.
KW - NMDA
KW - autoimmune encephalitis
KW - immunotherapy
KW - plasma cells
KW - receptor internalization
UR - http://www.scopus.com/inward/record.url?scp=85038819654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038819654&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.7b00319
DO - 10.1021/acschemneuro.7b00319
M3 - Article
C2 - 29077387
AN - SCOPUS:85038819654
SN - 1948-7193
VL - 8
SP - 2586
EP - 2595
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 12
ER -